Juniper Pharmaceuticals is developing therapeutics that address unmet medical needs in women’s health. The Company's current pipeline leverages the 505(b)(2) regulatory pathway with new formulations of existing pharmaceuticals. Juniper's current intravaginal ring product candidates are JNP-0101, an oxybutynin IVR for the treatment of overactive bladder in women; JNP-0201, a combination estrogen + progesterone IVR for menopausal symptoms; and, JNP-0301, a progesterone IVR for the prevention of preterm birth in women with a short cervical length at mid-pregnancy.